美东时间本周四，美国新冠疫苗研发“领跑者”Moderna 在一项疫苗研发的关键专利案中败诉，这可能导致其正在研发的关键产品新冠疫苗 mRNA-1273 处于进退两难的境地，意味着 Moderna 可能要支付一定专利许可费或是被迫推迟 mRNA-1273 研发。Moderna 向美国商标专利局（The U.S. Patent and Trademark Office）申诉生物制药...
Moderna与BioNTech的新冠mRNA疫苗使用N1-methylpseudouridine (1mψ)取代尿苷(U)进行核苷修饰,显著降低了mRNA的先天免疫应答。相比之下,作为mRNA三巨头之一的CureVac或许因为在mRNA分子修饰方面存在专利问题,所以采用了未经修饰的尿苷,通过序列优化...
Moderna:我们没有侵权 美东时间本周四,美国新冠疫苗研发“领跑者”Moderna 在一项疫苗研发的关键专利案中败诉,这可能导致其正在研发的关键产品新冠疫苗 mRNA-1273 处于进退两难的境地,意味着 Moderna 可能要支付一定专利许可费或是被迫推迟 mRNA-1273 研发。 Moderna 向美国商标专利局(The U.S. Patent and Trademark ...
The investigational vaccine known as mRNA-1273 protected mice from infection withSARS-CoV-2, thevirusthat causesCOVID-19, according to research published today inNature. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of theNational Institutes of Health, and th...
Moderna曾于11月16日发布三期临床试验首次中期功效分析,基于95例确诊病例,其中安慰剂组观察到90例确诊病例,而mRNA-1273组观察到5例,疫苗有效率为94.5%。 美联储主席鲍威尔在为12月1日美国国会参议院银行业委员会听证会准备的讲稿里表示,近期新冠肺炎疫苗消息对中期前景非常正面,但疫苗仍面临若干不确定性和严峻挑战,...
The U.S. Patent Trial and Appeal Board (PTAB) has rejected Moderna’s challenge to the last of three patents granted to Arbutus Biopharma covering the delivery technology used in Moderna’s front-running COVID-19 messenger RNA (mRNA) vaccine candidate mRNA-1273. [Moderna]...
Best known, of course, are Moderna’s vaccines against infectious diseases, including mRNA-1273, the vaccine against the Novel coronavirus (SARS-CoV-2), which was granted emergency use authorization in December, 2020. In all, the company now has 21 programs in its pipeline with 11 in ...
The world is aware of NIAID’s deep institutional commitment to the Moderna Vaccine. Moderna’s novel MRNA vaccine is a career vanity project for certain powerful NIAID officials who have nurtured the platform for years. NIAID apparently owns half of Moderna’s patent. At least six NIAID...
It should also be noted mRNA-1273 wasco-developedby Moderna and researchers at Fauci's NIAID Vaccine Research Center. That Moderna has a vested interest in mRNA-1273 is obvious, but so too do the taxpayer-funded NIAID researchers, several of whom"are inventors on US Patent Application No. ...
Patent Rights The vast majority of mRNA vaccines have gone to wealthy countries and there have been sketchy plans to make these on African soil. But because Moderna said it wouldn't enforce the patent rights on its vaccine, scientists have been able to reverse engineer it via a special WHO-...